Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. - Test2 - elhamkhani - TriplyDB

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.

http://www.wikidata.org/entity/Q33986172

about

Molecular mechanisms of cisplatin resistance in cervical cancer Role of copper transporters in platinum resistance Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer Systems biology of cisplatin resistance: past, present and future The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: a meta-analysis of literatures and datasets Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC The role of subcutaneous adipose tissue in supporting the copper balance in rats with a chronic deficiency in holo-ceruloplasmin.Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy.Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C Regulation of Cisplatin cytotoxicity by cu influx transporters.Integrin αV modulates the cellular pharmacology of copper and cisplatin by regulating expression of the influx transporter CTR1.EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin Specificity protein 1 (sp1) oscillation is involved in copper homeostasis maintenance by regulating human high-affinity copper transporter 1 expression.Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy Different gap junction-propagated effects on cisplatin transfer result in opposite responses to cisplatin in normal cells versus tumor cells.Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer.Expression of the copper transporters hCtr1, ATP7A and ATP7B is associated with the response to chemotherapy and survival time in patients with resected non-small cell lung cancer.Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy.Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers.Mechanistic basis for overcoming platinum resistance using copper chelating agents.Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H2O2 generation: antagonism by tetrathiomolybdate.Vitamin B6 metabolism influences the intracellular accumulation of cisplatin.Hyperthermic potentiation of cisplatin by magnetic nanoparticle heaters is correlated with an increase in cell membrane fluidity Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.Targeting drug transport mechanisms for improving platinum-based cancer chemotherapy.A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells A Comprehensive Review on the Genetic Regulation of Cisplatin-induced Nephrotoxicity Transcriptome analysis of copper homeostasis genes reveals coordinated upregulation of SLC31A1,SCO1, and COX11 in colorectal cancer.Deregulation of let-7e in epithelial ovarian cancer promotes the development of resistance to cisplatin.Bioavailable copper modulates oxidative phosphorylation and growth of tumors.Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals.NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.Ammonium tetrathiomolybdate treatment targets the copper transporter ATP7A and enhances sensitivity of breast cancer to cisplatin Characterization of a monoclonal antibody capable of reliably quantifying expression of human Copper Transporter 1 (hCTR1)Anticancer activity of metal complexes: involvement of redox processes.Advances in personalized therapy for lung cancer.Opportunities and hurdles in the treatment of BRCA1-related breast cancer.

P2860

Q26746228-4119C236-2293-4E1A-9E34-65BB9F7D3E64 Q26767028-93509190-3814-4A99-BC80-E94DF8897FC0 Q26863490-18AC94ED-C1BA-49F2-A463-A5CCA2FA927D Q26863585-3D26AB3C-0055-40D1-9763-7A5C8D8E4C10 Q28074028-18AC07E2-90FD-46A1-B8D9-49CD9C348A34 Q28478252-FE03DD1D-556A-43A2-8BBC-B1B7186A8681 Q33594575-7618E29C-2B1B-410A-810C-0E4C8027C2A5 Q33798999-97E69206-ABBC-419D-93EE-1845445BD71E Q33875938-A70E24D3-FD3E-4B56-A692-3A2337EE4BFB Q34159386-46A6DF4C-4A96-4E56-8E47-80994D28063B Q34232178-D8B3BC87-C8C5-46A5-A2FD-13F9F25DA55E Q34512688-6E31AC31-041E-43D9-9536-15DB3803C8B1 Q34781192-BDDC0490-4D9B-44AF-85F4-4AE18759C1DF Q35558444-A4590C84-1F57-446C-8AD6-A94B8F435096 Q35674891-BE283A6E-CB72-486E-9761-B46861398D9E Q35776756-7E485A2B-AD03-4F67-9D2E-5B94A5839AE7 Q35869320-4D0F114C-4221-46F5-82FB-62B25C22C9DE Q35895396-5C05E53B-33FB-4E59-A91E-A1D8A6956752 Q35909674-30435AB5-9F72-4749-84FC-8576C42B039E Q36085960-837C2813-681B-4513-9667-725DDAF6E2E5 Q36243650-06617AA3-4114-44CC-A1BB-25E071545EDB Q36280333-978BBBBB-4125-41DE-95AE-C5B6981A18E0 Q36392693-60F6F860-8504-4ED7-869C-76DCE4D17235 Q36557426-C7994524-1DB1-4397-AD16-2D03A36CBDDE Q36654372-679B622C-A68D-4DB5-91B6-A4CBBBFD93CF Q36672759-8C71FFF4-05ED-4D3C-BD2B-90D3833119AB Q36817080-2B78E6F9-5A61-4FFA-BC5C-1215D5E8BA56 Q36841450-D6F5A76E-E21B-4C85-A76D-F250B99318DB Q36852560-77F83563-1DCC-409F-B523-5F989116F725 Q36906569-6C5A944E-6325-4DD6-8ED0-3012FBF1855E Q37148790-59CA373C-85D6-42A9-8EDC-43761D409661 Q37275739-8547D7FA-C28C-4B97-ACF3-F6D7410126A3 Q37353035-49F75426-B846-4031-BDCA-984D8B6AB9AA Q37470105-B8325D43-9E14-4C3E-B065-1ED5F5B2961D Q37536566-23313AF8-D0BD-4F94-879E-CEB5E9DED7FA Q37686235-88D45344-2897-46DE-A63C-5ACAFFCD45BC Q37707059-90ECF9AF-60D1-4B36-A44F-9DF396A4EFA3 Q37833099-E64CE9F5-2B61-42FA-8D4C-75AC55BAA579 Q38127786-A9114B25-44A2-40E5-BC14-6FC01472DBD6 Q38129725-CEC363A3-5DFA-46E6-87E1-455477ADFEA2

P2860

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.

http://www.wikidata.org/entity/Q33986172

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.

@ast

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.

@en

type

label

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.

@ast

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.

@en

prefLabel

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.

@ast

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.

@en

P1433

Q33986172-BC550528-DE22-42A4-BBA7-5A8E58D6A33F

P1476

Q33986172-CA7061F1-7644-4BD0-AD8C-869ED51E0E61

P2093

Q33986172-80DB6555-9D14-4BC4-8A1C-AFAD97DFCE88

Q33986172-A1D1AE54-186D-427F-B4C5-BDF2616F4507

Q33986172-B7435732-AFD1-4159-982A-E8F7F4FAA687

Q33986172-C4A00E95-2665-482B-BC62-EEBEB7E0BD53

P2860

Q33986172-0007EE74-16B6-40E3-AE55-41E084F8D256

Q33986172-057CA3A9-B2B1-41EF-8927-F70C1891ECDC

Q33986172-0638D051-EC47-4D51-9C66-0D9EFF1E37F9

Q33986172-09998197-19C1-4D19-923B-BBAF0677E83C

Q33986172-09B5FD6C-E3E7-45D3-9FE6-7AB4016594C0

Q33986172-0C56B8D0-2808-4237-A946-01055EB281DE

Q33986172-19383612-FDE8-4DEE-A419-70D910D2997C

Q33986172-24E9EA4F-EEB7-4C0F-BDDD-72BA653D138E

Q33986172-29E96A4B-0225-41F6-817C-77BC250F52BE

Q33986172-312C955C-42AF-4D72-A1CC-0EA6B33AB7D3

P304

Q33986172-C4765A9F-E32C-4773-9113-344A6ABA7B81

P31

Q33986172-82A92567-3F2E-4E73-A880-F2C4E41A1552

P356

Q33986172-7376D53B-DD5C-4884-9E26-30D3175D083C

P433

Q33986172-9976B5C6-4D17-4C77-B353-90C901023473

P478

Q33986172-E1D1018D-22FA-4601-B655-4B0D05529D8B

P577

Q33986172-E46520A4-A285-4E0D-8ED9-47024D2A83B3

P5875

Q33986172-5A0AA99A-173A-41A3-93FA-440A16DB3653

P698

Q33986172-DB68A03F-FB40-45E4-9F37-62CF9202221F

P932

Q33986172-DCA17216-DAC6-46B8-BC2D-9EA3E052EF91

P356

J.CCR.2010.04.011

P1433

P1476

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.

@en

P2093

Douglas Hanahan

http://www.w3.org/2001/XMLSchema#string

Frank McCormick

http://www.w3.org/2001/XMLSchema#string

Karen Smith-McCune

http://www.w3.org/2001/XMLSchema#string

Seiko Ishida

http://www.w3.org/2001/XMLSchema#string

P2860

The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene

Characterization of mouse embryonic cells deficient in the ctr1 high affinity copper transporter. Identification of a Ctr1-independent copper transport system

Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1

Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance

Platinum containing regimens for metastatic breast cancer.

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.

The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene.

Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals.

Mechanisms for copper acquisition, distribution and regulation.

P304

574-583

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2010.04.011

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44667082

http://www.w3.org/2001/XMLSchema#string

P698

20541702

http://www.w3.org/2001/XMLSchema#string

P932

2902369

http://www.w3.org/2001/XMLSchema#string